Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evaxion Biotech ( (EVAX) ) just unveiled an update.
On October 3, 2025, Evaxion A/S announced that it will present new biomarker data for its AI-designed personalized cancer vaccine, EVX-01, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The data, stemming from an ongoing phase 2 trial, will contribute to the strong data package of EVX-01, which is being evaluated in combination with KEYTRUDA® for advanced melanoma. The presentation aims to highlight the vaccine’s efficacy and the predictive power of Evaxion’s AI-Immunology™ platform, potentially impacting the company’s industry positioning and offering significant insights for stakeholders.
The most recent analyst rating on (EVAX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by its financial challenges, despite strong revenue growth and positive developments in R&D and partnerships. The technical analysis suggests neutral momentum, while valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with financial stability and strategic progress, but regulatory and market challenges remain significant risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion is a pioneering TechBio company based in Denmark, leveraging its AI-Immunology™ platform to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company focuses on creating personalized vaccines and has a clinical-stage oncology pipeline and a preclinical infectious disease pipeline.
Average Trading Volume: 1,378,152
Technical Sentiment Signal: Hold
Current Market Cap: $34.3M
For a thorough assessment of EVAX stock, go to TipRanks’ Stock Analysis page.